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Abstract
Background: Overweight and obesity are well-known risk factors for cardiometabolic diseases including hypertension,
myocardial infarction, stroke, and type 2 diabetes in the general population. Survivors of childhood brain tumors (SCBT)
are at risk of premature mortality, and recent evidence suggests that these cardiometabolic diseases are potential
emerging determinants of survival and quality of life. Therefore, the rates of overweight and obesity in this population
need to be examined to assess their impact on outcomes. The objective of this systematic review is to examine the
prevalence of overweight and obesity in SCBT. The secondary aim of this review is to evaluate whether SCBT have
higher adiposity compared to the general population.
Methods: Searches will be conducted in MEDLINE, CINAHL, EMBASE, Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, PubMed, and Database of Abstracts of Reviews of Effect. For gray
literature, we will search ProQuest Dissertations and Theses A&I and Web of Science. Two reviewers will independently
screen all articles against predetermined eligibility criteria and complete data abstraction, risk of bias, and quality
assessments. The primary outcome includes the prevalence of overweight or obesity. The secondary outcomes involve
waist-to-hip ratio, waist-to-height ratio, body fat percentage, and skinfold thickness. Meta-analysis will be performed
when two or more studies with similar design, populations, and outcomes are available.
Discussion: This review will summarize current data on the prevalence of overweight and obesity in SCBT. This will
help the development of an understanding of the scale of overweight and obesity in this population and guide the
design of interventions that will improve outcomes.
Systematic review registration: PROSPERO CRD42016051035
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Background
Recent advances in the management of pediatric brain
tumors have significantly improved survival rates [1, 2].
However, the new record longevity noted in Survivors of
Childhood Brain Tumors (SCBT) is being hindered by
the emergence of new comorbidities including cardio-
metabolic diseases like hypertension, myocardial infarc-
tion, stroke, and type 2 diabetes [3–13]. The current
global overweight and obesity epidemic has been blamed
for the rise of these cardiometabolic disorders in the
general population, but the scale of overweight and
obesity and its role in driving adverse outcomes in survi-
vors is unknown.
Of note, SCBT have several risk factors that predispose
them to overweight and obesity. These include impaired
satiety signals, lower physical activity, impaired mobility
and coordination, pain, disrupted sleep, mental health
concerns, pituitary hormonal deficiencies, and medica-
tions [14–17]. To further understand the contribution of
overweight and obesity to cardiometabolic risk in SCBT,
there is a need to determine its scale in SCBT. This will
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inform the design of interventions to target overweight
and obesity and their risk factors to improve cardiomet-
abolic outcomes, quality of life, and survival rates in this
population.
In this systematic review, the epidemiological data on
the prevalence of overweight and obesity in SCBT will
be evaluated. The primary aim of this review is to deter-
mine whether SCBT have higher rates of overweight or
obesity compared to non-cancer counterparts. The
secondary aim of this review is to evaluate whether
SCBT have higher adiposity compared to the general
population.
Methods
This protocol is developed according to the Preferred
Reporting Items for Systematic Review and Meta-
Analysis-Protocols (PRISMA-P) statement [18, 19]
(Additional file 1).
Literature search
Searches will be conducted in MEDLINE, CINAHL,
EMBASE, Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, PubMed,
and Database of Abstracts of Reviews of Effect. The fol-
lowing concepts along with their synonyms will be used in
the search: pediatric, brain tumors, overweight/obesity,
and survivors. A search strategy will be developed in con-
sultation with a senior health sciences librarian with
expertise in systematic reviews. We will not set any re-
strictions on publication date, but will restrict our search
to English language publications. A full search strategy for
MEDLINE is reported in Table 1.
To identify grey literature, we will search ProQuest
Dissertations and Theses A&I and Web of Science. The
search in the latter database will be limited to “Confer-
ence Proceedings Citation Index-Science-1990-present.”
We will then search for relevant publications from the
first and last authors of the relevant conference abstracts
to identify articles originating from the work presented
in the abstracts. The reference lists of eligible studies
and relevant reviews will also be searched to identify any
additional studies. Searches will be updated to capture
recent publications by setting publication date
restrictions.
The search results will be de-duplicated in EndNote
X7 [20] and then exported into an excel file to screen
for eligible titles and abstracts. The full texts of relevant
records will then be retrieved to screen against the eligi-
bility criteria.
Study selection and eligibility criteria
Two independent reviewers, who will meet after each
stage to resolve conflicts and achieve consensus, will
screen the title and abstract of each record. A third
reviewer will be consulted when disagreements persist.
The two reviewers will then independently screen the
full text of the relevant studies identified from the title
and abstract screening.
This review will include SCBT diagnosed under
18 years of age. The following eligibility criteria will be
applied: (1) Primary research articles with observational
study design including longitudinal cohort, cross-
sectional, or case-control studies. (2) Sample size of ≥10
patients as previously described [21]. (3) Assessment of
prevalence of overweight or obesity and/or body com-
position using measures including Body Mass Index
(BMI), BMI z-score, BMI percentile, waist-to-hip ratio,
waist-to-height ratio, body fat, and skinfold thickness.
The screening process and results will be reported in a
PRISMA flow diagram, as previously described [22–24]
(Fig. 1).
Data collection
We developed a data abstraction form that will be
piloted by two reviewers on two eligible studies. Com-
ments will then be incorporated to finalize the form for
this specific systematic review. The abstracted data will
include publication information of title, authors’ names,
journal name, year of publication, as well as the city and
country of publication. We will also collect study details
including setting, study design, eligibility criteria, sample
size, study duration, and funding source. Outcome mea-
sures, primary findings, and conclusions will be collected
as well.
We will extract survivors’ characteristics including age
at diagnosis of brain tumor, age at study enrollment, and
sex. We will also extract brain tumor details including
brain tumor type and location and treatment details
such as treatment period, duration since treatment com-
pletion, and types of treatments received including
radiotherapy, chemotherapy, and surgery or combination
therapies with these modalities. If the study has a non-
cancer comparison group, we will document the type
and source of non-cancer controls used and abstract the
same data except for tumor- and treatment-related
variables.
Two reviewers will perform data abstraction independ-
ently, followed by a discussion to resolve discrepancies.
A third reviewer will intervene to resolve persisting dif-
ferences. In studies that report the data from multiple
cancer types as aggregates, data specific to the brain
tumor group will be extracted either through published
subgroup data or by contacting the research team to ac-
quire the data. We will also contact the corresponding
authors of a published work in attempts to obtain any
missing data.
The primary outcome for this review is the prevalence
of overweight or obesity estimated by BMI, BMI z-score,
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or BMI percentile. Secondary outcomes include waist-
to-hip ratio, waist-to-height ratio, body fat percentage,
and skinfold thickness.
Risk of bias and quality assessment
Two reviewers will independently assess the risk of bias
of the eligible studies using the Newcastle-Ottawa Scale
(NOS) for observational studies [25]. The NOS will be
adapted from its original version by considering a previ-
ously used modified version [26], so that the scale is
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33 choroid plexus papilloma*.ab,ti,kf.
34 ((brain or central nervous system or CNS or brainstem or brain stem
or cerebel* or cerebr* or hypothalam* or ventric* or intracranial or
midline or choroid plexus or infratentorial or supratentorial or
neuroectoderm* or germ cell*) adj5 (tumo?r* or neoplasm* or
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42 exp Body Composition/
43 (body adj3 (mass* or size* or composition*)).ab,ti,kf.
44 (fat* adj3 (mass* or body or abdominal* or intra-abdominal* or












55 waist to height ratio*.ab,ti,kf.
56 adipos*.ab,ti,kf.
57 ((waist* or hip* or abdominal*) adj3 circumference*).ab,ti,kf.
58 (weight* adj3 (gain* or change* or fluctuat*)).ab,ti,kf.
59 waist-hip ratio*.ab,ti,kf.
60 waist to hip ratio*.ab,ti,kf.
61 skinfold thickness*.ab,ti,kf.
62 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47
or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or
59 or 60 or 61
63 Survivors/




68 ((post or off or after) adj5 (treatment* or therap*)).ab,ti,kf.
69 ((treatment* or therap* or cancer* or disease* or event* or
progression*) adj5 free).ab,ti,kf.
70 63 or 64 or 65 or 66 or 67 or 68 or 69
71 9 and 35 and 62 and 70
72 limit 71 to english language
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specific to this review. The reviewers will meet and dis-
cuss their decisions to include articles and to resolve any
disagreement. In the case of persisting conflict, a third
reviewer will be consulted.
This adapted NOS evaluates five items pertaining to risk
of bias due to sample selection and classification (two
items), confounding factors (one item), missing data (one
item), and measurement errors (one item). For each item,
the risk of bias is rated on a scale of 0 (high risk of bias),
1–2 (moderate risk of bias), and 3 (low risk of bias). The
risk of bias is rated as unclear if not enough information is
provided. Descriptions with examples for each level of risk
of bias are provided (Additional file 2).
The overall risk of bias is rated as low when all five
items have low risk of bias or high when one or more
items have high risk of bias. The overall risk of bias is
considered to be moderate when not all items have low
risk of bias, but there are no items with high risk of bias.
If one of the items is rated as unclear, the overall risk of
bias will be reported as unclear as well.
Furthermore, we will use the Grading of Recommen-
dations, Assessment, Development, and Evaluation
(GRADE) guideline [27] to evaluate the overall quality of
evidence including the risk of bias, inconsistency, indir-
ectness, imprecision, and publication bias to determine
the overall quality of evidence for each outcome.
Fig. 1 PRISMA flow diagram
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Statistical analysis
We will perform meta-analysis if two or more studies of
similar design and population characteristics can be
identified for each outcome. We expect high heterogen-
eity across studies. The possible sources of heterogeneity
include age at diagnosis, duration and types of treat-
ment, and brain tumor type and location. Therefore, we
will perform meta-analysis using a random effects model
if more than ten studies are eligible and will perform
both random effects and fixed effects models if less than
ten studies are identified [28].
Dichotomous and continuous outcomes will be reported
as pooled odds ratio and standardized mean difference with
95% confidence intervals, respectively. In studies where
multiple measurements are done, we will include the out-
comes measured with the longest follow-up reported.
Both inconsistency index (I2) and P values from the
chi-square test for homogeneity will be considered to
determine the level of heterogeneity among the included
studies. The threshold set by the Cochrane Collaboration
will be used to interpret I2, with >75% representing con-
siderable heterogeneity. A P value of <0.10 will be used
to determine statistical significance [29]. If meta-analysis
is not appropriate, heterogeneity will be evaluated by de-
scribing and comparing the study samples, methods, and
designs across studies. We will perform subgroup meta-
analysis by sex and receipt of radiotherapy, chemother-
apy, and surgery or combination therapies with these
modalities if appropriate, as it has been reported that
female SCBT are at higher risk of obesity than males
[7, 8, 11]. In addition, to test the impact of outliers
and studies with high risk of bias on the results, we
will perform sensitivity analysis by excluding these studies
if ten or more studies can be identified for an outcome.
To maintain the power of the results, we will not per-
form sensitivity analyses if less than ten studies are eli-
gible. If ten or more studies are identified, we will use a
contour-enhanced funnel plot to investigate publication
bias [30]. The plot asymmetry will be determined by
Egger’s test and visual inspection [30]. Otherwise, we
will estimate publication bias based on the number of
relevant conference abstracts that did not have published
articles originating from the work presented in the
abstracts [31].
We will use Review Manager Version 5.3 Software
(RevMan 5.3) [32] to conduct the meta-analysis. If
Egger’s test is appropriate, Comprehensive Meta-
Analysis Software Version 3 (CMA 3.0) will be used in-
stead [33]. A comprehensive table for summary of find-
ings with narrative description will be reported when a
meta-analysis is not appropriate.
We will report the results of this systematic review in
accordance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guidelines
using the PRISMA checklist [22, 23]. We will also docu-
ment the date and reasons for any amendments to the
protocol.
Discussion
While record numbers of children are surviving the
diagnosis of brain tumors, this survival is burdened by
the high rate of comorbidities and premature mortality
[10, 12, 34]. To improve the quality of the cure, detailed
understanding of the factors driving comorbidities in
SCBT is likely to provide therapeutic entry points to
improve outcomes.
Recent evidence suggests that new emerging risk fac-
tors may be contributing to mortality in this population.
With increasing longevity, SCBT are at risk of type 2
diabetes and cardiovascular diseases that appear rela-
tively early in life [3–6, 9]. This argues for a premature
aging process, whereby diseases of old age are appearing
earlier in life in SCBT. This may indicate that similar
overweight or obesity levels may have a disproportion-
ately negative impact on SCBT when compared to the
general population, and interventions are needed to
stem the occurrence of overweight and obesity and
reduce their burden in survivors. Notable limitations of
this systematic review include the restriction of the
search strategy to English language publications only, as
this may lead to missing information from non-English
literature. In addition, if the heterogeneity of the studies
is high, this will preclude the performance of a meta-
analysis. Nevertheless, this review will identify gaps in
knowledge and inform better clinical practice in identify-
ing overweight and obesity and will help inform the need
for specifically designed interventions to tackle over-
weight and obesity in SCBT and improve outcomes.
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